For decades, daily low-dose aspirin has been a cornerstone in preventing secondary cardiovascular events like heart attack and stroke. However, a new international analysis of nearly 29,000 patients suggests the antiplatelet medication clopidogrel may offer a more effective long-term strategy, demonstrating a 14% reduction in major cardiovascular events compared to aspirin. The findings, published this week, are prompting renewed discussion among cardiologists about optimal post-event care for patients with coronary artery disease and coudl influence prescribing practices.
For patients with coronary artery disease, a common antiplatelet medication, clopidogrel, may offer a significant advantage over daily low-dose aspirin in preventing major cardiovascular events, a new analysis suggests.
Daily low-dose aspirin has long been a standard recommendation for individuals with coronary artery disease, particularly as they age. However, emerging evidence is prompting a reevaluation of this practice, with researchers now suggesting a potentially more effective alternative.
An international team of cardiologists recently analyzed data from nearly 29,000 patients and found that clopidogrel – a medication that prevents blood platelets from clumping together – reduced the risk of heart attack, stroke, or cardiovascular death by approximately 14% compared to aspirin. The findings, based on a review of seven randomized trials, indicate clopidogrel’s effectiveness extends across different age groups, ethnicities, and body types.
Notably, the analysis revealed that clopidogrel did not increase the risk of excessive bleeding, a common concern with antiplatelet therapies. The study focused on patients who had already experienced a cardiovascular event, such as a heart attack or stroke, and were using the medications as secondary prevention.
Researchers concluded that these results support clopidogrel as a preferred long-term antiplatelet strategy over aspirin for patients with established coronary artery disease. Currently, clopidogrel is typically prescribed for a short period after a heart attack or stroke. The American Heart Association currently recommends clopidogrel over aspirin for individuals with peripheral artery disease, due to its greater effectiveness in preventing major vascular events.
While some recent studies have hinted at potential benefits of clopidogrel in coronary artery disease, it has traditionally been reserved for patients unable to take aspirin. However, some cardiologists argue that the data supporting this recommendation is outdated. The authors of the recent analysis explained that the evidence base for long-term aspirin use largely stems from smaller studies conducted before the advent of modern medications and revascularization strategies.
The researchers gathered data from all relevant randomized trials comparing clopidogrel and aspirin, ultimately selecting seven studies encompassing the nearly 29,000 patients. Approximately half received clopidogrel as a single antiplatelet therapy, while the other half received aspirin.
After more than five years of follow-up, patients taking clopidogrel were less likely to experience serious cardiovascular or cerebrovascular events than those taking aspirin. Even individuals of East Asian descent – who are known to sometimes have a reduced response to short-term clopidogrel therapy – showed improved outcomes with clopidogrel compared to aspirin.
This research isn’t the only indication that alternatives to aspirin may be warranted. A 2020 article published in the American Heart Association journal Circulation called for further research from cardiologists at Johns Hopkins University, Harvard University, Massachusetts General Hospital, and the National University of Ireland Galway.
The team acknowledged the established role of aspirin in the early treatment of heart attacks, but noted that studies evaluating daily aspirin use for cardiovascular disease were conducted in the 1970s and 1980s, with limited long-term follow-up and often without utilizing low-dose aspirin regimens. They suggested it may be time to reassess the risks and benefits of low-dose aspirin, particularly among older adults who are at higher risk of bleeding.
